774-P: Impact of Transition to Tandem Control-IQ on Sleep Awakenings in Youth with Type 1 Diabetes (T1D) and Their Parents

• Published in: Diabetes (New York, N.Y.) Vol. 71; no. Supplement_1
• Main Authors: KARAMI, ANGELA J., PYLE, LAURA, VIGERS, TIMOTHY B., JOST, EMILY, WADWA, R. PAUL, COBRY, ERIN C.
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2022
• Subjects: Diabetes; Diabetes mellitus (insulin dependent); Diaries; Intelligence; Sleep
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db22-774-P

Youth with T1D and their parents are susceptible to diabetes-related nocturnal awakenings, which have been associated with reduced sleep duration and quality. We conducted an observational study of youth with T1D starting on the Tandem Control-IQ (CIQ) hybrid closed-loop (HCL) system to evaluate the impact of system use on sleep. Thirty-nine youth (age 11.1±3.6 yrs, T1D duration 2.5±3.0 yrs, 54% male) and a parent (age 42.5±6.7 yrs, 18% male) completed sleep diaries capturing the number of and reasons for nocturnal awakenings over a 7-day period. Analyses compared diaries from before starting CIQ (baseline) to 3- and 6-months after starting CIQ using a zero-inflated Poisson mixed model with random intercept for participants. Youth and parents reported significantly fewer total awakenings per night at 3- and 6-months compared to baseline (Table) . A significant decrease in diabetes-related awakenings was observed after 6 months in youth but not in parents. Following CIQ initiation, fewer nocturnal awakenings were reported by parents and youth, with youth additionally reporting significantly fewer diabetes-related awakenings at 6 months. Due to the subjective nature of diaries, the number of true awakenings may be different. The results suggest that HCL technology may be beneficial in reducing sleep disruptions in youth and parents. Disclosure A.J.Karami: None. L.Pyle: None. T.B.Vigers: None. E.Jost: Other Relationship; Tandem Diabetes Care, Inc. R.Wadwa: Advisory Panel; Dompé, Consultant; Beta Bionics, Inc., Other Relationship; Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Eli Lilly and Company, Tandem Diabetes Care, Inc. E.C.Cobry: None.